Skip to content
ClinCalc Pro
Menu
Antimuscarinic — Overactive Bladder

Trospium Chloride

Brand names: Regurin, Regurin XL

Trospium chloride is an antimuscarinic agent used to treat urinary frequency, urgency and urge incontinence in adults with overactive bladder.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is a quaternary ammonium antimuscarinic that competitively blocks muscarinic receptors in the bladder, reducing detrusor contractions and increasing functional bladder capacity; its quaternary structure limits central nervous system penetration.

Prescribing in practice

  • It is contraindicated in urinary retention, significant gastrointestinal obstruction or severe gastrointestinal conditions, angle-closure glaucoma, myasthenia gravis and tachyarrhythmia.
  • It should be taken on an empty stomach before food, as food substantially reduces its absorption.
  • Caution is required in renal impairment and in older patients, with attention to overall anticholinergic burden.

Monitoring

Review symptom response after an adequate trial and monitor for anticholinergic adverse effects and urinary retention, especially in older patients.

Counselling the patient

  • Take the medicine before food on an empty stomach.
  • Report difficulty passing urine, and expect possible dry mouth and constipation.

Evidence & guidelines

Antimuscarinics are recommended by NICE for overactive bladder where conservative treatment is insufficient; see the SPC for administration advice.

Reference: NICE NG123 (Urinary Incontinence and OAB); STOPP/START v3; EAU OAB Guidelines 2024; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.